Search results for " Oral contraceptives"

showing 2 items of 2 documents

Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?

2013

""The primary aim of the study was to analyze the endometrioma recurrence rate in patients who underwent laparoscopic excision followed by postoperative long-term regimen of oral contraceptives (OCs).. . MATERIALS AND METHODS: 168 patients who underwent a conservative laparoscopic surgery for endometrioma, during the period between September 2009 and August 2010 in three university hospitals were studied. A long-term OCs therapy was offered to all women following surgery. Patients were randomly divided into three groups according to different progestins used (desogestrel, gestodene, dienogest). Women who refused a postoperative hormonal therapy served as control. Follow-up visits and transv…

minimally invasive gynecologic surgeryAdultmedicine.medical_specialtyEndometriosis endometrioma recurrencee oral contraceptives minimally invasive gynecologic surgery progestins dienogest.AdolescentNorpregnenesendometrioma recurrenceeEndometriosisEndometriosisKaplan-Meier EstimateDrug Administration Schedulelaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawSecondary PreventionHumansNandroloneMedicineIn patientOvarian DiseasesYoung adultLaparoscopyoral contraceptivesDesogestrelmedicine.diagnostic_testbusiness.industryObstetricsObstetrics and GynecologyEndometriosis Endometrioma recurrence Oral contraceptives Minimally invasive gynaecologic surgery Progestins DienogestGeneral MedicineLaparoscopic excisionmedicine.diseaseCombined Modality TherapySurgeryRegimenTreatment OutcomeDienogestchemistryprogestinsdienogestFemaleLaparoscopybusinessContraceptives OralFollow-Up Studies
researchProduct

Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment

2008

The discovery of the Janus kinase 2 Val617Phe mutation has brought new insights into the development of myeloproliferative disorders; however, the pathogenesis of essential thrombocythemia and its related thrombotic complications has not been completely understood. Although the Janus kinase 2 Val617Phe mutation confirms the initially suspected clonal character of the disease, factors influencing clonal transformation and expansion in the bone marrow have not been fully detected. Furthermore, patients affected by essential thrombocythemia who are carriers of the Janus kinase 2 Val617Phe mutation show a higher incidence of venous thromboembolism both before, and at the time of diagnosis, comp…

Adultmedicine.medical_specialtyMutation MissenseOral contraceptiveEssential thrombocythemiaGastroenterologyContraceptives Oral HormonalPathogenesisMesenteric VeinsPortal thrombosisMyeloproliferative DisordersInternal medicinemedicineHumansPlateletSplanchnic CirculationJanus kinase 2Janus kinase 2biologyessential thrombocythemia Janus kinase 2 oral contraceptives portal thrombosisKinaseEssential thrombocythemiaVascular diseasebusiness.industryThrombosisHematologyGeneral Medicinemedicine.diseaseThrombocytopeniaThrombosisEndocrinologybiology.proteinFemalebusiness
researchProduct